PDCD1 and cutaneous melanoma: While the development of immune checkpoint inhibitors, targeting cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and programmed cell death-1 (PD-1), have dramatically increased the outcome for patients with advanced cutaneous melanoma, a comparable clinical benefit has not been observed for unresectable/metastatic UM.